Collaboration Forms: A Case Study

452 Words1 Page

Specialty medications are high-cost and generally not available in generic forms. Manufacturers always have specific programs to assist providers and patients to use their specialty drugs. By joining those programs, patients are required to sign authorization forms that allow PHI to be released by SP to manufacturers. Different manufacturers have divergent authorization forms while HIPAA and many states have their own requirements and information on the forms. It is a challenge for manufacturers to create authorization forms that can meet states’ demand. Therefore, using original authorization forms created by manufacturers might violate either HIPAA or state laws, where SPs are located at. SPs need to have their own compliance team to handle authorizations. The article lists two options that SPs can choose to proceed with authorization forms. The first option is SPs can …show more content…

This step will help SPs to prevent violation when releasing PHI to external parties. Also, SPs need to have a system that can track if the authorizations are signed, dated, and in place for each patients. This process will ensure that SPs can properly disclose PHI to manufacturers. Sharing patients’ information with manufacturers play very important part in optimizing patients’ health outcomes while on specialty medications. The information will help researchers have further understanding about side effects and mechanism of actions, which were not observed in clinical trial phases. Patients’ authorizations are the keys of disclosing PHI to manufacturers. Therefore, HIM professionals’ roles are to ensure that authorization forms signed by patients must meet HIPAA and state regulations as well as manufacturers’ criteria of collected information. The HIPAA rules have six core requirements on PHI authorization

Open Document